Cargando…

FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic

The prevalence of obesity or metabolic syndrome is increasing worldwide (globally metabodemic). Approximately 25% of the adult general population is suffering from nonalcoholic fatty liver disease (NAFLD), which has become a serious health problem. In 2020, global experts suggested that the nomencla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sumida, Yoshio, Yoneda, Masashi, Tokushige, Katsutoshi, Kawanaka, Miwa, Fujii, Hideki, Yoneda, Masato, Imajo, Kento, Takahashi, Hirokazu, Eguchi, Yuichiro, Ono, Masafumi, Nozaki, Yuichi, Hyogo, Hideyuki, Koseki, Masahiro, Yoshida, Yuichi, Kawaguchi, Takumi, Kamada, Yoshihiro, Okanoue, Takeshi, Nakajima, Atsushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917687/ https://www.ncbi.nlm.nih.gov/pubmed/33672864 http://dx.doi.org/10.3390/life11020143

Ejemplares similares

Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
por: Sumida, Yoshio, et al.
Publicado: (2020)

Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods
por: Yoneda, Masato, et al.
Publicado: (2017)

Eradication of hepatitis C virus with direct‐acting antivirals improves glycemic control in diabetes: A multicenter study
por: Takahashi, Hirokazu, et al.
Publicado: (2020)

A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD
por: Kawaguchi, Takumi, et al.
Publicado: (2018)

Infection phase is a predictor of pruritus in patients with hepatitis B virus infection
por: Oeda, Satoshi, et al.
Publicado: (2019)

Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population
por: Sumida, Yoshio, et al.
Publicado: (2012)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Modification of a simple clinical scoring system as a diagnostic screening tool for non‐alcoholic steatohepatitis in Japanese patients with non‐alcoholic fatty liver disease
por: Nakamura, Akinobu, et al.
Publicado: (2013)

Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 Diabetes
por: Ishiba, Hiroshi, et al.
Publicado: (2020)

LDL-Migration Index (LDL-MI), an Indicator of Small Dense Low-Density Lipoprotein (sdLDL), Is Higher in Non-Alcoholic Steatohepatitis than in Non-Alcoholic Fatty Liver: A Multicenter Cross-Sectional Study
por: Imajo, Kento, et al.
Publicado: (2014)

Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease
por: Sumida, Yoshio, et al.
Publicado: (2020)

Association of Serum Albumin Levels and Long-Term Prognosis in Patients with Biopsy-Confirmed Nonalcoholic Fatty Liver Disease
por: Takahashi, Hirokazu, et al.
Publicado: (2023)

Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD
por: Takahashi, Hirokazu, et al.
Publicado: (2021)

The FIB-4 Index Predicts the Development of Liver-Related Events, Extrahepatic Cancers, and Coronary Vascular Disease in Patients with NAFLD
por: Kamada, Yoshihiro, et al.
Publicado: (2022)

Discordant pathological diagnosis of non‐alcoholic fatty liver disease: A prospective multicenter study
por: Kuwashiro, Takuya, et al.
Publicado: (2019)

Association of Serum and Fecal Bile Acid Patterns With Liver Fibrosis in Biopsy-Proven Nonalcoholic Fatty Liver Disease: An Observational Study
por: Kasai, Yuki, et al.
Publicado: (2022)

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020
por: Tokushige, Katsutoshi, et al.
Publicado: (2021)

Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin
por: Ogawa, Yuji, et al.
Publicado: (2018)

Are Platelets Count Useful for Detecting the Grade of Steatosis?
por: Imajo, Kento, et al.
Publicado: (2015)

SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum
por: Kamada, Yoshihiro, et al.
Publicado: (2022)

Elastography Techniques for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease
por: Honda, Yasushi, et al.
Publicado: (2020)

Mac-2 binding protein glycosylation isomer, the FIB-4 index, and a combination of the two as predictors of non-alcoholic steatohepatitis
por: Kiyoaki, Ito, et al.
Publicado: (2022)

Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease
por: Nakajima, Atsushi, et al.
Publicado: (2021)

Involvement of a periodontal pathogen, Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease
por: Yoneda, Masato, et al.
Publicado: (2012)

Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers
por: Kawaguchi, Takahisa, et al.
Publicado: (2018)

A 3-step approach to predict advanced fibrosis in nonalcoholic fatty liver disease: impact on diagnosis, patient burden, and medical costs
por: Kobayashi, Takashi, et al.
Publicado: (2022)

Current and future pharmacological therapies for NAFLD/NASH
por: Sumida, Yoshio, et al.
Publicado: (2017)

Glycogen Hepatopathy: An Under-recognized Hepatic Complication of Uncontrolled Type 1 Diabetes Mellitus
por: Sumida, Yoshio, et al.
Publicado: (2017)

COVID-19-associated liver injury (COVALI): role of hepatologists
por: Sumida, Yoshio, et al.
Publicado: (2021)

Deficiency of eNOS exacerbates early-stage NAFLD pathogenesis by changing the fat distribution
por: Nozaki, Yuichi, et al.
Publicado: (2015)

Deficiency of iNOS-derived NO accelerates lipid accumulation-independent liver fibrosis in non-alcoholic steatohepatitis mouse model
por: Nozaki, Yuichi, et al.
Publicado: (2015)

Epidemiology, Pathogenesis, and Diagnostic Strategy of Diabetic Liver Disease in Japan
por: Sumida, Yoshio, et al.
Publicado: (2020)

Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease
por: Kumagai, Erina, et al.
Publicado: (2016)

Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study
por: Honda, Yasushi, et al.
Publicado: (2017)

Soluble CD14 Levels Reflect Liver Inflammation in Patients with Nonalcoholic Steatohepatitis
por: Ogawa, Yuji, et al.
Publicado: (2013)

Decrease in fasting insulin secretory function correlates with significant liver fibrosis in Japanese non‐alcoholic fatty liver disease patients
por: Araki, Norimasa, et al.
Publicado: (2020)

Use of Mac‐2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis
por: Kamada, Yoshihiro, et al.
Publicado: (2017)

FIB nanostructures
por: Wang, Zhiming M
Publicado: (2013)

The Clinical Difference in the Platelet Counts between Liver Cirrhosis with Nonalcoholic Fatty Liver Disease and Hepatitis C Virus
por: Ikarashi, Yuichi, et al.
Publicado: (2017)

Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease
por: Shoji, Hirotaka, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ht49nrfd11ripq66nhq69vfpod